China's Fosun Pharma in the running for $2b Novartis assets

China's Fosun Pharma in the running for $2b Novartis assets

Photo: Reuters

Manuel Baigorri

11 May, 2018

Apollo Global Management Aurobindo Pharma CVC Capital Partners Fosun Group Novartis Shanghai Fosun Pharmaceutical (Group) Co. Ltd

Printed by Unregistered user on Wed, 17 Dec 2025 10:45:42 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

Read more from Greater China

Warburg Pincus signs deal to invest in business service provider Acclime

MetaX shares surge 700% on debut as China’s AI chip push gathers speed